Answers are grounded in this paper and cite their sources.
Expert review demonstrates the therapeutic and disease-modeling potential of induced pluripotent stem cell-derived cardiomyocytes, highlighting their role in advancing personalized cardiac medicine.
Disease models are essential for understanding cardiovascular disease pathogenesis and developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology has generated significant enthusiasm for its potential application in basic and translational cardiac research. Patient-specific iPSC-derived cardiomyocytes offer an attractive experimental platform to model cardiovascular diseases, study the earliest stages of human development, accelerate predictive drug toxicology tests, and advance potential regenerative therapies. Harnessing the power of iPSC-derived cardiomyocytes could eliminate confounding species-specific and interpersonal variations and ultimately pave the way for the development of personalized medicine for cardiovascular diseases. However, the predictive power of iPSC-derived cardiomyocytes as a valuable model is contingent on comprehensive and rigorous molecular and functional characterization.
No takes yet. Share an insight, caveat, or question.
Karakikes et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: